Design of cancer-specific antitumor agents based on aziridinylcyclopent[b]indoloquinones

Journal of Medicinal Chemistry

Volumn 43, Issue 3, 2000, Pages 457-466

  Xing, Chengguo ^a   Wu, Ping ^a   Skibo, Edward B ^a   Dorr, Robert T ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AZIRIDINYLCYCLOPENT[B]INDOLOQUINONE DERIVATIVE; AZIRIDINYLMITOSENE; DIHYDROLIPOAMIDE DEHYDROGENASE; MITOMYCIN C; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA ALKYLATION; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AZIRIDINES; CATTLE; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; INDOLES; KINETICS; LIVER; MELANOMA; MODELS, MOLECULAR; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM TRANSPLANTATION; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0034628483     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990466w     Document Type: Article

References (32)

1. Skibo, E. B. Pyrrolobenzimidazoles in cancer treatment. Expert. Opin. Ther. Patents 1998, 8, 673-701.
2. Zhou, R.; Skibo, E. B. Chemistry of the Pyrrolo[1,2-α]benzimidazole Antitumor Agents: Influence of the 7-Substituent on the Ability to Alkylate DNA and Inhibit Topoisomerase II. J. Med. Chem. 1996, 39, 4321-4331.
3. Skibo, E. S.; Gordon, S.; Bess, L.; Boruah, R.; Heileman, J. Studies of Pyrrolo[1,2-α]benzimidazole Quinone DT-Diaphorase Substrate Activity, Topoisomerase II Inhibition Activity, and DNA Reductive Alkylation. J. Med. Chem. 1997, 40, 1327-1339.
4. Spanswick, V. J.; Cummings, J.; Smyth, J. F. Current issues in the enzymology of mitomycin C metabolic activation. Gen. Pharmacol. 1998, 31, 539-544.
5. Bailey, S. M.; Lewis, A. D.; Knox, R. J.; Patterson, L. H.; Fisher, G. R.; Workman, P. Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: A detailed kinetic study and analysis of metabolites. Biochem. Pharmacol. 1998, 56, 613-621.
6. Schulz, W. G.; Nieman, R. A.; Skibo, E. B. Evidence for DNA Phosphate Backbone Alkylation and Cleavage by Pyrrolo[1,2-α]benzimidazoles, Small Molecules Capable of Causing Sequence Specific Phosphodiester Bond Hydrolysis. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 11854-11858.
7. Boruah, R. C.; Skibo, E. B. A Comparison of the Cytotoxic and Physical Properties of Aziridinyl Quinone Derivatives Based on the Pyrrolo(1,2-α]benzimidazole and Pyrrolo[1,2-α]indole Ring Systems. J. Med. Chem. 1994, 37, 1625-1631.
8. Skibo, E. B.; Islam, I.; Schulz, W. G.; Zhou, R.; Bess, L.; Boruah, R. The Organic Chemistry of the Pyrrolo[1,2-α]benzimidazole Antitumor Agents. An Example of Rational Drug Design. Synlett 1996, 297-309.
9. Zimmer, H.; Lankin, D. C.; Horgan, S. W. Oxidations with Potassium Nitrosodisulfonate (Fremy's Radical). The Teuber Reaction. Chem. Rev. 1971, 71, 229-246.
10. Liu, R.; Zhang, P.; T. Gan, T.; Cook, J. M. Regiospecific Bromination of 3-Methylindoles with NBS and Its Application to the Concise Synthesis of Optically Active UnusualTryptophans Present in Marine Cyclic Peptides. J. Org. Chem. 1997, 62, 7447-7456.
11. Acheson, R. M. Some Experiments with Cyclopentanes. J. Chem. Soc. 1956, 4232-4237.
12. Paull, D. K.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and Analysis of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092.
13. Alvarez, M.; Robey, R.; Sandor, V.; Nishiyama, K.; Matsumoto, Y.; Paull, K.; Bates, S.; Fojo, T. Using the national cancer institute anticancer drug screen to assess the effect of mrp expression on drug sensitivity profiles. Mol. Pharmacol. 1998, 54, 802-814.
14. Skibo, E. B.; Islam, I.; Heileman, M. J.; Schulz, W. G. Structure-Activity Studies of Benzimidazole-Based DNA-Cleaving Agents. Comparison of Benzimidazole, Pyrrolubenzimidazole and Tetrahydropyridobenzimidazole Analogues. J. Med. Chem. 1994, 37, 78-92.
15. Griswold, D. P. Consideration of the Subcutaneously Implanted B16 Melanoma as a Screening Model foe Potential Anticancer Agents. Cancer Chemother. Rep. 1972, 3, 315-324.
16. Riley, R. J.; Workman, P. DT-diaphorase and Cancer Chemotherapy. Biochem. Pharmacol. 1992, 43, 1657-1669.
17. Rauth, A. M.; Goldberg, Z.; Misra, V. DT-diaphorase: Possible roles in cancer chemotherapy and carcinogenesis. Oncol. Res. 1997, 9, 339-349.
18. Wu, K. B.; Knox, R.; Sun, X. Z.; Joseph, P.; Jaiswal, A. K.; Zhang, D.; Deng, P. S. K.; Chen, S. Catalytic properties of NAD(P)H: quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch. Biochem. Biophys. 1997, 347, 221-228.
19. Kelsey, K. T.; Ross, D.; Traver, R. D.; Christiani, D. C.; Zuo, Z. F.; Spitz, M. R.; Wang, M.; Xu, X.; Lee, B. K.; Schwartz, B. S.; Wiencke, J. K. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br. J. Cancer 1997, 76, 852-854.
20. Beall, H. D.; Mulcahy, R. T.; Siegel, D.; Traver, R. D.; Gibson, N. W.; Ross, D. Metabolism of Bioreductive Antitumor Compounds by Purified Rat and Human DT-Diaphorase. Cancer Res. 1994, 54, 3196-3201.
21. Bailey, S. M.; Wyatt, M. D.; Friedlos, F.; Hartley, J. A.; Knox, R. J.; Lewis, A. D.; Workman, P. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. Br. J. Cancer 1997, 76, 1596-1603.
22. Franck, R. W.; Tomasz, M. The Chemistry of Mitomycins. In The Chemistry of Antitumor Agents; Wilman, D. E., Ed.; Blackie & Sons Ltd.: Glasgow, Scotland, 1990; pp 379-394.
23. Remers, W. A. Mitomycins and Porfiromyein. In The Chemistry of Antitumor Antibiotics, Volume 1; John Wiley & Sons Inc.: New York, 1979; pp 221-276.
24. Hendriks, H. R.; Pizao, P. E.; Berger, D. P.; Kooistra, K. L.; Bibby, M. C.; Boven, E.; Dreef-van der Meulen, H. C.; Henrar, H. H.; Fiebig, H. H.; Double, J. A.; Hornstra, H. W.; Pinedo, H. M.; Workman, P.; Schwartsmann, G. EO9: A Novel Bioreductive Alkylating Indoloquinone With Prefential Solid Tumour Activity and Lack of Bone Marrow Toxicity in Preclinical Models. Eur. J. Cancer 1993, 29A, 8997-906.
25. Naylor, M. A.; Jaffar, M.; Nolan, J.; Stephens, M. A.; Butler, S.; Patel, K. B.; Everett, S. A.; Adams, G. E.; Stratford, I. J. 2-cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: Structure-activity in vitro and efficacy in vivo. J. Med. Chem. 1997, 40, 2335-2346.
26. Maliepaard, M.; deMol, N. J.; Tomasz, M.; Gargiulo, D.; Janssen, L. H. M.; vanDuynhoven, J. P. M.; vanVelzen, E. J. J.; Verboom, W.; Reinhoudt, D. N. Mitosene-DNA adducts. Characterization of two major DNA monoadducts formed by 1,10-bis(acetoxy)-7-methoxymitosene upon reductive activation. Biochemistry 1997, 36, 9211-9220.
27. Islam, I.; Skibo, E. B. Synthesis and Physical Studies of Azamitosene and Iminoazamitosene Reductive Alkylating Agents. Iminoquinone Hydrolytic Stability, Syn/Anti Isomerization, and Electrochemistry. J. Org. Chem. 1980, 55, 3195-3205.
28. Cummings, J.; Spanswick, V. J.; Tomasz, M.; Smyth, J. F. Enzymology of mitomycin C metabolic activation in tumour tissue - Implications for enzyme-directed bioreductive drug development. Biochem. Pharmacol. 1998, 56, 405-414.
29. Palom, Y.; Belcourt, M. F.; Kumar, G. S.; Arai, H.; Kasai, M.; Sartorelli, A. C.; Rockwell, S.; Tomasz, M. Formation of a major DNA adduct of the mitomycin metabolite 2,7-diaminomitosene in EMT6 mouse mammary tumor cells treated with mitomycin C. Oncol. Res. 1998, 10, 509-521.
30. Schulz, W. G.; Islam, E.; Skibo, E. B. Pyrrolo[1,2-α]benzimidazole-Based Quinones and Iminoquinones. The Role of the 3-Substituent on Cytotoxicity. J. Med. Chem. 1995, 38, 109-118.
31. Skibo, E. B.; Xing, C. Chemistry and DNA Alkylation Reactions of Aziridinyl Quinones: Development of an Efficient Alkylating Agent of the Phosphate Backbone. Biochemistry 1998, 37, 15199-15213.
32. Höjeberg, B.; Blomberg, K.; Stenberg, S.; Lind, C. Biospecific Adsorption of Hepatic DT-Diaphorase on Immobilized Dicoumarol. Arch. Biochem. Biophys. 1981, 207, 205-216.